Arrowstreet Capital Limited Partnership Has $23.51 Million Stock Position in The Cooper Companies, Inc. (NASDAQ:COO)

Arrowstreet Capital Limited Partnership grew its position in The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 280.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 255,718 shares of the medical device company's stock after acquiring an additional 188,513 shares during the period. Arrowstreet Capital Limited Partnership owned 0.13% of Cooper Companies worth $23,508,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in Cooper Companies in the 4th quarter valued at about $691,000. Highland Capital Management LLC bought a new stake in shares of Cooper Companies during the fourth quarter valued at approximately $4,004,000. Caprock Group LLC acquired a new stake in shares of Cooper Companies in the fourth quarter valued at approximately $282,000. Franklin Resources Inc. raised its position in Cooper Companies by 194.0% in the 3rd quarter. Franklin Resources Inc. now owns 48,892 shares of the medical device company's stock worth $5,265,000 after purchasing an additional 32,260 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in Cooper Companies by 6.6% during the 3rd quarter. Principal Financial Group Inc. now owns 238,305 shares of the medical device company's stock worth $26,295,000 after buying an additional 14,687 shares in the last quarter. 24.39% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently commented on COO. Needham & Company LLC reissued a "hold" rating on shares of Cooper Companies in a research note on Friday, March 7th. Robert W. Baird cut their target price on shares of Cooper Companies from $117.00 to $107.00 and set an "outperform" rating on the stock in a research report on Friday, March 7th. Citigroup lowered their price target on shares of Cooper Companies from $115.00 to $110.00 and set a "buy" rating for the company in a research report on Friday, March 7th. JPMorgan Chase & Co. cut their price objective on shares of Cooper Companies from $120.00 to $110.00 and set an "overweight" rating on the stock in a report on Friday, March 7th. Finally, BNP Paribas raised shares of Cooper Companies to a "hold" rating in a report on Thursday, March 13th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $110.25.

Remove Ads

Cooper Companies Trading Down 2.5 %

NASDAQ:COO traded down $1.81 on Tuesday, reaching $71.50. The company's stock had a trading volume of 1,525,313 shares, compared to its average volume of 1,374,378. The Cooper Companies, Inc. has a 1-year low of $70.51 and a 1-year high of $112.38. The business's 50-day moving average price is $86.17 and its two-hundred day moving average price is $95.43. The firm has a market cap of $14.30 billion, a PE ratio of 36.67, a PEG ratio of 2.25 and a beta of 1.01. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91.

Cooper Companies (NASDAQ:COO - Get Free Report) last released its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share for the quarter, meeting the consensus estimate of $0.92. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The company had revenue of $964.70 million during the quarter, compared to analysts' expectations of $981.25 million. Equities research analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.